Why Did Silexion Therapeutics Corp. (SLXN) Plunge 20.19%?

On June 2, 2025, Silexion Therapeutics Corp. (SLXN) experienced a significant drop of 20.19% in pre-market trading, marking a notable decline in its stock performance.

Silexion Therapeutics Corp. (SLXN) has been in the spotlight recently due to several key developments. The company announced the suspension of Nasdaq trading, which led to a sharp decline in its stock price. This decision has raised concerns among investors about the company's future prospects and financial stability.

Despite the recent setbacks, there are indications that Silexion Therapeutics may have promising opportunities ahead. The potential expansion of its drug SIL-204's application beyond pancreatic cancer could significantly increase its market potential. This development suggests that the company might be on the cusp of broader market opportunities, which could positively impact its stock performance in the long run.